Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

New Biomarker Enables Early and Accurate Parkinson’s Diagnosis

Researchers validate cerebrospinal fluid test using iRS technology with over 90% accuracy, paving the way for early intervention and therapeutic advancements.

Image
Image

Overview

  • The PRODI Center and betaSENSE have identified misfolded alpha-synuclein in cerebrospinal fluid as a reliable biomarker for early Parkinson's diagnosis.
  • The patented immuno-infrared sensor (iRS) technology directly detects protein misfolding, achieving sensitivity and specificity metrics exceeding 90%.
  • Findings were validated in two independent clinical cohorts totaling 134 participants from research centers in Bochum and Kassel, Germany.
  • The biomarker offers potential for therapeutic monitoring, enabling researchers to measure treatment effects in clinical trials targeting Parkinson's disease.
  • Results, published in EMBO Molecular Medicine on April 25, 2025, mark a significant step toward integrating this diagnostic tool into clinical workflows.